I would personally temper my expectations here a little on near term profitability.
Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.
EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.
If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.
The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.
- Forums
- ASX - By Stock
- EYE
- Nova Eye Medical (EYE) Discussion
Nova Eye Medical (EYE) Discussion, page-2480
-
- There are more pages in this discussion • 599 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.5¢ |
Change
-0.005(2.27%) |
Mkt cap ! $49.19M |
Open | High | Low | Value | Volume |
22.0¢ | 22.5¢ | 21.5¢ | $130.0K | 589.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 506631 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 9070 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 506631 | 0.215 |
5 | 149761 | 0.210 |
2 | 29540 | 0.205 |
11 | 131320 | 0.200 |
2 | 8000 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 9070 | 1 |
0.230 | 67523 | 3 |
0.235 | 15000 | 1 |
0.240 | 28253 | 1 |
0.245 | 26000 | 2 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online